Oncology · Data CollectionTrial Updateclinicalmid-term

Study on Remote Physiologic Data Collection in Cancer by MSK

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/22/2026, 6:31:07 PM

Assessment confidence: 51% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The initiation of this study by Memorial Sloan Kettering Cancer Center is significant as it aims to enhance the understanding of cancer diagnosis and treatment response through innovative data collection methods. This could lead to more personalized treatment strategies, impacting how oncology companies approach patient management. Regulatory context from FDA (Oncology (Cancer)/Hematologic Malignancies Approval Notifications) supports the near-term read. Assessment grounded in 24 ranked evidence items (3 high-relevance).

Strategic Assessment

The strongest clinical anchor is Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol (ClinicalTrials.gov), entity match (memorial sloan kettering cancer center). In Oncology · Data Collection, 4 regulatory and 4 competitive items passed relevance filtering for Memorial Sloan Kettering Cancer Center. If successful, the findings could influence treatment protocols and patient management strategies, potentially affecting market share for oncology products and services.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sponsor/company relevance (pfizer). Secondary pressure from Ubiquitination signature identified in neuroendocrine prostate cancer with therapeutic implications. This study may enhance understanding of cancer diagnosis and treatment response, potentially influencing future therapeutic approaches.

Regulatory Outlook

Regulatory risk is concentrated around Oncology (Cancer)/Hematologic Malignancies Approval Notifications (FDA). Regulatory pathway relevance (approval). The study's outcomes may inform future regulatory considerations regarding data collection methods and their implications for treatment efficacy and safety.

Key Risks

Elevated medium regulatory exposure for Memorial Sloan Kettering Cancer Center could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on Memorial Sloan Kettering Cancer Center through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

If successful, the findings could influence treatment protocols and patient management strategies, potentially affecting market share for oncology products and services.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Upside for Memorial Sloan Kettering Cancer Center may improve if Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (ClinicalTrials.gov) delivers favorable follow-through.
How advancements in data collection could impact patient management strategies and treatment personalization.

What Would Change This Assessment

This becomes more urgent if Monitor outcomes related to data collection methods and their correlation with cancer treatment responses.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
Outcome from Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol would change the regulatory/clinical read.
Outcome from Oncology (Cancer)/Hematologic Malignancies Approval Notifications would change the regulatory/clinical read.

Supporting Evidence

Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Study Data Technical Conformance Guide - Technical Specifications Document
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol
ClinicalTrials.govhigh relevance
Entity match (memorial sloan kettering cancer center)
FDA document
View source
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
Ubiquitination signature identified in neuroendocrine prostate cancer with therapeutic implications
Humanexa Signalsmedium relevance
Moderate corpus alignment
Study Optimizes Immunotherapy for Pancreatic Adenocarcinoma Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment
NCI's MATCH Trial Evaluates Genetic Testing for Targeted Therapy in Advanced Cancers
Humanexa Signalsmedium relevance
Moderate corpus alignment

RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Burden of HPV-associated cancers in Peruvian men: Evidence from national health data.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Early effects of HPV vaccination on high-grade cervical intraepithelial neoplasia in Brazil: Evidence from outpatient data.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Memorial Sloan Kettering Cancer Center
oncology drug developers
cancer treatment protocols

Commercial impact

medium

If successful, the findings could influence treatment protocols and patient management strategies, potentially affecting market share for oncology products and services.

Regulatory impact

medium

The study's outcomes may inform future regulatory considerations regarding data collection methods and their implications for treatment efficacy and safety.

What to watch

Monitor outcomes related to data collection methods and their correlation with cancer treatment responses.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.